The trademark application was filed by AstraZeneca AB, a corporation established under the laws of the Kingdom of Sweden (the "Applicant"). The application was published for oppositions on July 6, 2022, and it was registered by office on October 13, 2022 without any oppositions.
The application was filed in English (French was selected as the second language).